The data shows that in the last 12 months, multinational drugmakers have also done equally well in the Indian market in terms of growth rate
If this goes through, drugmakers will have the liberty to raise the prices of these drugs by up to 10 per cent every year
Steady improvement in the US and India market growth keeps analysts positive
Cipla is investing Rs 600 crore to set up a manufacturing plant for biosimilars in South Africa
Govt banned 344 drug combinations over weekend, including Abbott's codeine-based cough syrup